US clears new option for gastroenteropancreatic tumours

29th January 2018 Uncategorised 0

US regulators have cleared the use of Novartis group Advanced Accelerator Applications’ Lutathera to treat certain gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

More: US clears new option for gastroenteropancreatic tumours
Source: News